NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
Neuraxis, Inc. (NRXS)
Company Research
Source: GlobeNewswire
CARMEL, Ind., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the third quarter period ended September 30, 2025. 3Q25 Financial highlights Revenues increased 22% year over year to $811 thousand in 3Q25 compared to $667 thousand in 3Q24.Operating loss in 3Q25 increased 27% year over year compared to 3Q24 due to increased sales and marketing efforts.Cash balance was $4.4 million as of September 30, 2025. Subsequently, the Company secured an additional $2.8 million through an at-the-market equity offering and warrant exercises in October 2025. Recent Operational Highlights Awarded first ever FDA clearance for the treatment of pain in Functional Dyspepsia (FD) with associated nausea symptoms in the adult patient populationSecured key academic society guidelines recomme
Show less
Read more
Impact Snapshot
Event Time:
NRXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRXS alerts
High impacting Neuraxis, Inc. news events
Weekly update
A roundup of the hottest topics
NRXS
News
- NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain [Yahoo! Finance]Yahoo! Finance
- NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal PainGlobeNewswire
- NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered LivesGlobeNewswire
- NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025GlobeNewswire
- NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient PopulationGlobeNewswire
NRXS
Sec Filings
- 11/12/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 10/24/25 - Form 8-K
- NRXS's page on the SEC website